These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28215618)

  • 21. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.
    Hollingworth W; Jones T; Reeves BC; Peto T
    BMJ Open; 2017 Oct; 7(10):e018289. PubMed ID: 29061629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.
    Vottonen P
    Acta Ophthalmol; 2018 Feb; 96 Suppl A109():1-46. PubMed ID: 29468838
    [No Abstract]   [Full Text] [Related]  

  • 25. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.
    Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA
    Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aflibercept versus ranibizumab for treating persistent diabetic macular oedema.
    Vandekerckhove KR
    Int Ophthalmol; 2015 Aug; 35(4):603-9. PubMed ID: 25989873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-VEGF therapy to treat diabetic macular edema].
    Takamura Y
    Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pharmacoeconomic analysis of anti-angiogenic drugs for diabetic macular edema].
    Krysanov IS; Klabukova DL; Krysanova VS; Ermakova VY
    Vestn Oftalmol; 2024; 140(2):112-120. PubMed ID: 38742507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.
    Prescrire Int; 2015 Sep; 24(163):207. PubMed ID: 26417628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.
    Akiyode O; Major J; Ojo A
    J Pharm Pract; 2017 Oct; 30(5):534-540. PubMed ID: 27166390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
    Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
    Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 37. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 39. Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Gabrielle PH; Creuzot-Garcher C
    Lancet; 2024 Mar; 403(10432):1111-1113. PubMed ID: 38461837
    [No Abstract]   [Full Text] [Related]  

  • 40. Updates on the Clinical Trials in Diabetic Macular Edema.
    Demirel S; Argo C; Agarwal A; Parriott J; Sepah YJ; Do DV; Nguyen QD
    Middle East Afr J Ophthalmol; 2016; 23(1):3-12. PubMed ID: 26957834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.